Navigation Links
ChromaDex Announces Financial Results for Second Quarter 2011
Date:8/11/2011

IRVINE, Calif., Aug. 11, 2011 /PRNewswire/ -- ChromaDex Corporation (OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries, today announced financial results for the second quarter of 2011. On a reported basis and calculated in accordance with U.S. Generally Accepted Accounting Principles (U.S. GAAP), ChromaDex announced total revenues of approximately $1.9 million and a net loss attributable to common stockholders of $0.03 per share for the three-month period ended July 2, 2011. As of July 2, 2011, cash, cash equivalents, and marketable securities totaled over $2.0 million.

"We made substantial strides related to pTeroPure in the recent quarter, continuing to build a very strong foundation for the business expansion that is underway," stated Frank Jaksch, CEO and co-founder of ChromaDex. "Our results for the quarter did not yet reflect the business building accomplishments we achieved during the period, but we believe the foundation created, with pTeroPure achieving GRAS (generally recognized as safe) status, the upcoming launch of BluScience at GNC, as well as our licensing agreement with beverage industry giant Cott, places ChromaDex in a very strong position from which to grow long-term shareholder value. Beyond pTeroPure, we remain committed to growing our product and service offerings to include other novel ingredients with large market potential in the rapidly growing natural products industry. The recently announced in-license of intellectual property from Cornell, related to the unique Nicotinamide Riboside compound, is evidence of that continued focus."

Additional Financial Results & NotesOn a reported basis, ChromaDex recorded revenue of $1,937,976 during the second quarter of 2011 as compared to $2,033,861 for the same period in 2010. The net loss attributable to common stockholders for the quarter ended July 2, 2011 was $1,842,569 as compared to a net loss of $303,529 for the same period in 2010. The net loss in the second quarter of 2011 was significantly impacted by an increase in non-cash, share-based compensation expense related to the stock options that were granted following the May 20, 2010 private placement and the restricted stock that was issued to certain employees and consultants. When the net loss is adjusted to exclude the effects of non-cash charges associated with share-based compensation expense, a "non-GAAP" presentation, the net loss for the second quarter of 2011 is $1,073,864 and the loss per share for the second quarter of 2011 is $0.02.

About ChromaDexChromaDex is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. The company has an impressive pipeline of new ingredients, including its pTeroPure brand on which it has worldwide, exclusive patent rights.

ChromaDex Forward-Looking StatementsAny statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.Investor Inquiries:Liviakis Financial Communications, Inc.John M. Liviakis, President415-389-4670John@Liviakis.comChromaDex Contact Laura CarneyExecutive Assistant to the CEO, President, and CFO10005 Muirlands Blvd, Suite G, Irvine, CA 92618949-419-0288LauraC@chromadex.comChromaDex Corporation and SubsidiariesCondensed Consolidated Statements of Operations (Unaudited)For the Three Month Periods Ended July 2, 2011 and July 3, 2010July 2, 2011July 3, 2010Sales

$
,937,976$
2,033,861Cost of sales

1,357,0581,258,172Gross profit580,918775,689Operating expenses:Sales and marketing

565,975228,351General and administrative

1,849,733840,538Operating expenses2,415,7081,068,889Operating loss (1,834,790)(293,200)Nonoperating income (expenses):Interest income

430397Interest expense

(8,209)(10,726)Nonoperating loss(7,779)(10,329)Net loss$
(1,842,569)$
(303,529)Basic and Diluted loss per common share

$
(0.03)$
(0.01)Basic and Diluted average common shares outstanding

65,001,97943,623,403See Notes to Condensed Consolidated Financial Statements.Quantitative Reconciliation of the differences between the non-GAAP measure and the associated comparable GAAP measureCondensed Consolidated Statements of Operations (Unaudited, US GAAP) For the Three Month Periods Ended July 2, 2011 and July 3, 2010July 2, 2011July 3, 2010Sales

$   1,937,976$   2,033,861Cost of sales

1,357,0581,258,172Gross profit580,918775,689Operating expenses:Sales and marketing

565,975228,351General and administrative

1,849,733840,538Operating expenses

2,415,7081,068,889Operating loss (1,834,790)(293,200)Nonoperating income (expenses):Interest income

430397Interest expense

(8,209)(10,726)Nonoperating loss(7,779)(10,329)Net loss$ (1,842,569)$
(303,529)Basic and Diluted loss per common share

$
(0.03)$
(0.01)Basic and Diluted  average common shares outstanding

65,001,97943,623,403Effects of Non-cash Charges associated with  Share-based Compensation Expense For the Three Month Periods Ended July 2, 2011 and July 3, 2010July 2, 2011July 3, 2010Sales

$
-$
-Cost of sales

--Gross profit--Operating expenses:Sales and marketing

--General and administrative

(768,705)(230,858)Operating expenses

(768,705)(230,858)Operating income768,705230,858Nonoperating income:Interest income

--Interest expense

--Nonoperating income--Net income$
768,705$
230,858Basic and Diluted income per common share

$
.01$
.01Basic and Diluted  average common shares outstanding

65,001,97943,623,403Condensed Consolidated Statements of Operations Excluding Share-based Compensation (Non-GAAP Presentation) For the Three Month Periods Ended July 2, 2011 and July 3, 2010July 2, 2011July 3, 2010Sales

$   1,937,976$   2,033,861Cost of sales

1,357,0581,258,172Gross profit580,918775,689Operating expenses:Sales and marketing

565,975228,351General and administrative

1,081,028609,680Operating expenses

1,647,003838,031Operating loss (1,066,085)(62,342)Nonoperating income (expenses):Interest income

430397Interest expense

(8,209)(10,726)Nonoperating loss(7,779)(10,329)Net loss$ (1,073,864)$
(72,671)Basic and Diluted loss per common share

$
(0.02)$
(0.00)Basic and Diluted  average common shares outstanding

65,001,97943,623,403
'/>"/>

SOURCE ChromaDex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ChromaDex Partners With Kappa Bioscience to Provide Quality Control Methods, Tools and Services for Vitamin K2
2. ChromaDex and Bruker Optics Sign Agreement to Expedite Dietary Supplement Testing for Compliance With FDA Good Manufacturing Practice Requirements
3. Nutraceutical International Corporation Launches Product Featuring ChromaDexs pTeroPure™ Pterostilbene
4. Life Extension® Launches New Product Containing ChromaDexs pTeroPure® Pterostilbene
5. ChromaDex Licenses Additional Technology for pTeroPure® From the University of Mississippi
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 If ... Leaders Scholarship is any indication, the future is in ... at www.diabetesscholars.org by the Diabetes Scholars Foundation ... the way of academic and community service excellence. ... since 2012, and continues to advocate for people with ...
(Date:6/23/2016)... June 23, 2016 Revolutionary technology ... Oticon , industry leaders in advanced audiology and ... Oticon Opn ™, the world,s first internet connected ... for IoT devices.      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ... a number of ,world firsts,: , TwinLink™ ...
(Date:6/23/2016)... Pa. , June 23, 2016 The ... in an outpatient dialysis facility.  Treatments are usually 3 ... 6 hours per visit, including travel time, equipment preparation ... a patient, but especially grueling for patients who are ... of a skilled nursing and rehabilitation centers for some ...
Breaking Medicine Technology:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
Breaking Medicine News(10 mins):